These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24830724)

  • 1. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
    Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D
    Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
    PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
    J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
    Endo H; Okami J; Okuyama H; Nishizawa Y; Imamura F; Inoue M
    Oncogene; 2017 May; 36(20):2824-2834. PubMed ID: 27893711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
    Wendt MK; Williams WK; Pascuzzi PE; Balanis NG; Schiemann BJ; Carlin CR; Schiemann WP
    Neoplasia; 2015 Jan; 17(1):124-33. PubMed ID: 25622905
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
    Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.
    Zhang H; Liu W; Wang Z; Meng L; Wang Y; Yan H; Li L
    Tumori; 2018 Jun; 104(3):221-231. PubMed ID: 29714661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
    Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
    Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination.
    Kuo MH; Lee AC; Hsiao SH; Lin SE; Chiu YF; Yang LH; Yu CC; Chiou SH; Huang HN; Ko JC; Chou YT
    Cancer Res; 2020 Oct; 80(20):4426-4438. PubMed ID: 32816907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.